- Home
- BKE vs ARQT Comparison
BKE vs ARQT Comparison
Compare BKE & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKE
- ARQT
- Stock Information
- Founded
- BKE 1948
- ARQT 2016
- Country
- BKE United States
- ARQT United States
- Employees
- BKE N/A
- ARQT N/A
- Industry
- BKE Clothing/Shoe/Accessory Stores
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- BKE Consumer Discretionary
- ARQT Health Care
- Exchange
- BKE Nasdaq
- ARQT Nasdaq
- Market Cap
- BKE 3.0B
- ARQT 3.3B
- IPO Year
- BKE 1992
- ARQT 2020
- Fundamental
- Price
- BKE $57.70
- ARQT $30.97
- Analyst Decision
- BKE Hold
- ARQT Strong Buy
- Analyst Count
- BKE 1
- ARQT 7
- Target Price
- BKE $55.00
- ARQT $22.17
- AVG Volume (30 Days)
- BKE 476.0K
- ARQT 2.7M
- Earning Date
- BKE 11-21-2025
- ARQT 10-28-2025
- Dividend Yield
- BKE 6.80%
- ARQT N/A
- EPS Growth
- BKE 3.79
- ARQT N/A
- EPS
- BKE 4.09
- ARQT N/A
- Revenue
- BKE $1,277,894,000.00
- ARQT $317,929,000.00
- Revenue This Year
- BKE $7.09
- ARQT $85.27
- Revenue Next Year
- BKE $2.91
- ARQT $30.70
- P/E Ratio
- BKE $14.03
- ARQT N/A
- Revenue Growth
- BKE 4.67
- ARQT 129.21
- 52 Week Low
- BKE $33.12
- ARQT $10.57
- 52 Week High
- BKE $61.69
- ARQT $31.11
- Technical
- Relative Strength Index (RSI)
- BKE 58.62
- ARQT 75.88
- Support Level
- BKE $52.08
- ARQT $27.08
- Resistance Level
- BKE $56.82
- ARQT $31.10
- Average True Range (ATR)
- BKE 1.55
- ARQT 1.59
- MACD
- BKE 0.08
- ARQT 0.50
- Stochastic Oscillator
- BKE 88.04
- ARQT 98.36
About BKE Buckle Inc. (The)
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.